Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T cells for relapsed or refractory B-cell lymphoma
ChiCTR1800018111Phase 2Recruiting
- Sponsor
- Tongji Medical College
- Start
- Sep 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD19-targeted chimeric antigen receptor-modified T cells in mature B-cell lymphoma, sponsored by Tongji Medical College. Primary endpoints: white blood cell, platelet and 10 more. Started Sep 2018; status: recruiting.
02
Drugs
CD19-targeted chimeric antigen receptor-modified T cells
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on ChiCTR1800018111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018111.